Patents by Inventor Brian Ngo
Brian Ngo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11993601Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: GrantFiled: January 27, 2023Date of Patent: May 28, 2024Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Publication number: 20240169526Abstract: The present disclosure is for a system and a method for artificial intelligence (AI) based review of radiologic images as they are being read by a radiologist. The AI review is performed through the use of screen sharing and screen capture approaches allowing an AI model to analyze images without direct access to the raw image files. The AI review may compare user documented findings with AI model-based findings in order to identify discrepancies between the two. The discrepancies can be used as feedback for retraining the model and/or as feedback to the user to aid in education or track and/or improve an individual's review characteristics.Type: ApplicationFiled: November 10, 2023Publication date: May 23, 2024Inventors: Lawrence Ngo, Brian Blanchette, Jacob Johnson, Thomas Craig, Hongyi Zhang
-
Patent number: 11956349Abstract: A method is disclosed. The method comprises transmitting, by an access device to a communication device, a resource provider certificate and an access device certificate. Then, establishing a secure channel between the access device and the communication device using data from the resource provider certificate and the access device certificate. Then, transmitting to or receiving data from the communication device using the secure channel.Type: GrantFiled: October 29, 2018Date of Patent: April 9, 2024Assignee: Visa International Service AssociationInventors: Brian Sullivan, Dinah Sloan, Christian Aabye, Hao Ngo, Yuexi Chen, Fahimeh Rezaei
-
Patent number: 11891387Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.Type: GrantFiled: March 25, 2021Date of Patent: February 6, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
-
Publication number: 20230382902Abstract: 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R1, R2a, and R2b are defined herein.Type: ApplicationFiled: June 2, 2023Publication date: November 30, 2023Inventors: Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Jimmy T. Liang
-
Patent number: 11820766Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: GrantFiled: December 23, 2020Date of Patent: November 21, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Patent number: 11802111Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.Type: GrantFiled: September 21, 2021Date of Patent: October 31, 2023Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant
-
Publication number: 20230242531Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: ApplicationFiled: January 27, 2023Publication date: August 3, 2023Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Patent number: 11708359Abstract: 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R1, R2a, and R2b are defined herein.Type: GrantFiled: February 9, 2021Date of Patent: July 25, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Jimmy T. Liang
-
Publication number: 20230145249Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: ApplicationFiled: December 6, 2022Publication date: May 11, 2023Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Patent number: 11597728Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: GrantFiled: December 23, 2020Date of Patent: March 7, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Publication number: 20220372030Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.Type: ApplicationFiled: March 25, 2021Publication date: November 24, 2022Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
-
Publication number: 20220332713Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: ApplicationFiled: December 23, 2020Publication date: October 20, 2022Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Publication number: 20220315583Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: ApplicationFiled: December 23, 2020Publication date: October 6, 2022Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Publication number: 20220089538Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.Type: ApplicationFiled: September 21, 2021Publication date: March 24, 2022Inventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant
-
Publication number: 20210253565Abstract: 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R1, R2a, and R2b are defined herein.Type: ApplicationFiled: February 9, 2021Publication date: August 19, 2021Inventors: Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Jimmy T. Liang
-
Patent number: 11030781Abstract: Systems and methods for aggregating and storing different types of data, and generating interactive user interfaces for analyzing the stored data. In some embodiments, entity data is received for a plurality of entities from one or more data sources, and used to determine attribute values for the entities for one or more given time periods. The plurality of entities may be categorized into one or more entity groups, and aggregate attribute values may be generated based upon the entity groups. A first interactive user interface is generated displaying the one or more entity groups in association with the aggregated attribute values associated with the entity group. In response to a received indication of a user selection of an entity group, a second interactive user interface is generated displaying the one or more entities associated with the selected entity group, each entity displayed in association with the attribute values associated with the entity.Type: GrantFiled: September 18, 2019Date of Patent: June 8, 2021Assignee: Palantir Technologies Inc.Inventors: Sean Kelley, Dylan Scott, Ayush Sood, Kevin Verdieck, Izaak Baker, Eliot Ball, Zachary Bush, Allen Cai, Jerry Chen, Aditya Dahiya, Daniel Deutsch, Calvin Fernandez, Jonathan Hong, Jiaji Hu, Audrey Kuan, Lucas Lemanowicz, Clark Minor, Nicholas Miyake, Michael Nazario, Brian Ngo, Mikhail Proniushkin, Siddharth Rajgarhia, Christopher Rogers, Kayo Teramoto, David Tobin, Grace Wang, Wilson Wong, Holly Xu, Xiaohan Zhang
-
Publication number: 20200126011Abstract: Computer-implemented systems and methods are provided for analyzing healthcare-related entity performance. In one implementation, a method is implemented with one or more processors and includes receiving a request that includes one or more filter selections and accessing a data structure including information that specifies a plurality of categories of healthcare-related interactions associated with multiple healthcare-related entities. The method also includes identifying a set of categories from the plurality of categories based on the one or more filter selections and processing the information of the identified categories to provide performance information of one or more entities of the multiple healthcare-related entities in accordance with the one or more filter selections. The method further includes generating a user interface that includes the performance information indicating a performance of the one or more entities.Type: ApplicationFiled: September 25, 2019Publication date: April 23, 2020Inventors: Lekan Wang, Allen Chang, John Garrod, Sina Iman, Patrick Tardif, Antoine Llorca, Sebastian Bruckner, Cody Veal, Samuel Fendell, Christopher Lewis, Brian Ngo, Patrick Dunn, Sebastian Caliri, Hari Arul, Ajay Sudan, Michael Winlo, Isaac Gateno, Michael Glazer, Daniel Cervelli, Lauren Chaparro
-
Publication number: 20200102311Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: ApplicationFiled: September 27, 2019Publication date: April 2, 2020Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Publication number: 20200102303Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: ApplicationFiled: September 27, 2019Publication date: April 2, 2020Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang